Xtl Biopharmaceuticals annual capital expenditures (capex)
2015
2016
2019
2020
2024
Xtl Biopharmaceuticals Capital Expenditures (CapEx) Growth & History (XTLB)
Xtl Biopharmaceuticals's capital expenditures (capex) was $54,000 for fiscal 2024.
View full Xtl Biopharmaceuticals company overviewXtl Biopharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $54,000 | — | — |
| 2020 | 2020-12-31 | $1,000 | −$1,000 | −50.00% |
| 2019 | 2019-12-31 | $2,000 | — | — |
| 2016 | 2016-12-31 | $2,000 | $0 | 0.00% |
| 2015 | 2015-12-31 | $2,000 | — | — |
Xtl Biopharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, Xtl Biopharmaceuticals's capital expenditures (capex) increased from $2,000 to $54,000, a change of $52,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xtl Biopharmaceuticals source filings ↗